NICE Recommends First Vitiligo Treatment for Use in the NHS

The National Institute for Health and Care Excellence (NICE) has issued a positive recommendation for the first licensed treatment for vitiligo to be used in the NHS, providing a new option for more than 80,000 people in England living with the condition.

Vitiligo is a chronic autoimmune disorder in which the immune system attacks melanocytes, the cells responsible for skin pigmentation. This leads to pale or white patches on the skin, which can have a considerable effect on a person’s confidence, social interactions, and overall mental wellbeing. The condition is often more visible among people with darker skin tones, further increasing its impact.

Until now, people with vitiligo have had limited treatment options, mostly involving corticosteroid creams or light therapy, which require regular hospital visits. NICE’s latest recommendation supports the use of ruxolitinib cream (Opzelura), a topical therapy that acts on the underlying immune response linked to pigment loss.

Developed by Incyte, ruxolitinib cream is the first treatment shown to help restore natural skin colour by targeting specific immune pathways. The medicine, which inhibits JAK1 and JAK2 enzymes, works by reducing inflammation and allowing pigment-producing cells to recover. In clinical studies, people treated with the cream were more than four times as likely to regain natural facial colouring compared with placebo. Participants also reported visible improvements in skin appearance and reduced disease visibility.

Patient representatives welcomed the decision, noting that the condition can have psychological and social consequences and that access to an at-home topical treatment could ease the challenges associated with existing therapies. The new treatment may benefit teenagers and adults, particularly those aged 12 and older with non-segmental vitiligo that affects the face and who have not responded to other topical options.

Inthe United States, the U.S. Food and Drug Administration (FDA) has approved Opzelura for treating non-segmental vitiligo and atopic dermatitis in eligible patients. The product also holds approval in Europe for adults and adolescents aged 12 years and older with facial involvement. Incyte retains global rights for the development and commercialization of ruxolitinib cream, marketed commercially as Opzelura.

TheNICE recommendation marks the first time the NHS will have access to a treatment that directly addresses the disease process of vitiligo, offering patients a new, practical option for managing this long-term skin condition.